Sophia Abene

New meta-analysis at the 2025 vaccinology conference highlights the efficacy of maternal RSV vaccines, with calls for enhanced monitoring following safety issues with one candidate

SOF/VEL cured 98.9% of 7,027 hepatitis C cases globally, and peptide-decorated liposomes improved antifungal delivery against Candida species, and more

More than 80% of adults support COVID-19 vaccination, but hesitancy linked to side effects, geopolitics, and misinformation remains a challenge, says lead researcher Mahmud Sheku, MPH, MSc.

Zandraetta Tims-Cook, MD, MPH, highlights the need for inclusive HIV prevention strategies and discusses the potential of long-acting injectable PrEP in improving care and reducing disparities.

Posaconazole-loaded liposomes decorated with penetratin show up to 1300 times increased efficacy against biofilm formation and reduce fungal burden by 60% in murine models.

As therapies that impact the immune system become more common, patients are living longer but with increased susceptibility to infections, including viral, bacterial, fungal, and emerging diseases.

Therapeutic vaccines GS-2829 and GS-6779 demonstrate immune responses and strong safety profile, showing potential to contribute to global hepatitis B elimination efforts.

Multinational real-world analysis underscores the effectiveness of sofosbuvir/velpatasvir (SOF/VEL) across diverse populations and highlights the need for timely treatment initiation to improve patient outcomes.

Paul Feuerstadt, MD, discusses the safe and effective use of RBL in preventing C difficile recurrence with positive physician feedback and high patient benefit

75% effectiveness of RSV vaccines in adults aged 60 and older, along with key safety considerations and broadened recommendations for high-risk groups.

Regulatory action follows reports of serious adverse events during use in elderly individuals; vaccine remains authorized for younger age groups in the US and Europe with over 40,000 doses administered globally.

Phase 3 data link gut microbiome shifts to better mental health outcomes in patients treated with fecal microbiota, live-jslm.

Vibrant Wellness’ Jason Barker, ND, outlines prevention measures, diagnostic red flags, and advances in multiplex testing for tick-borne diseases.

LA County confirms 165 cases since 2024 with 29 in 2025 alone, including individuals without known risk factors.

Jennifer Cohn, MD, MPH, calls for better data, drug access, and care tracking to address gaps in treatment.

Jason Barker, ND, explains how in-house technology delivers highly sensitive specific and early detection of Borrelia infections and co-infections helping patients receive faster diagnosis and treatment

Michigan dairy worker's infection is linked to widespread H5N1 outbreaks, as new findings suggest increased transmission risk and moderate disease in mammals.

The Centers for Disease Control and Prevention (CDC) investigates backyard poultry-linked outbreak across 6 states, while FDA issues tomato recall over separate contamination concerns.

US outbreaks account for 93% of cases, North Dakota sees first case since 2011, and the Americas Region reports over 2,300 infections.

Jason Barker, ND, details how Vibrant’s platform raises diagnostic sensitivity from 63% to 100%, ensuring more accurate detection and faster treatment for Lyme disease and tick-borne infections.

Three different studies reveal blood signatures linked to symptoms, immune pathways tied to lung damage, and the efficacy of cognitive training for brain fog.

Despite political restructuring and funding cuts, the NIH’s Generation Gold Standard vaccine platform offers a promising solution for pandemic preparedness and global health resilience.

Andrew Lover, PhD, MPH, discusses the shifting landscape of tick-borne illnesses during Tick-Borne Disease Awareness Month.

Jason Barker, ND, explains how standard testing can miss coinfections and how Vibrant’s microarray improves sensitivity and efficiency in a single test.

Study supports the global need for targeted education to correct misconceptions and improve treatment adherence.

Sabrina Absalon, PhD, explains how antibiotic disruption of the apicoplast led to the discovery of PfAnchor, a key protein required for parasite division and survival.

The latest fungal-focused edition of the Centers for Disease Control and Prevention’s journal Emerging Infectious Diseases explores the global spread of antifungal resistance, rising cases of Aspergillus infections, and the detection of Histoplasma.

US cases already surged 210% in 2025, while ECDC reported a 786% increase in Europe, with 35,212 cases in 2024.

Novavax Vice President Matthew Rousculp on reactogenicity, vaccine hesitancy, and supporting informed decisions.

At ESCMID Global 2025, SHIELD study data show Novavax recipients experienced fewer adverse effects and missed less work compared with those who received the Pfizer-BioNTech COVID-19 vaccine.